In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas

Antimicrob Agents Chemother. 2015;59(6):3627-9. doi: 10.1128/AAC.04945-14. Epub 2015 Mar 30.

Abstract

In this study, susceptibilities were determined for AZD0914, a spiropyrimidinetrione DNA gyrase inhibitor, azithromycin, doxycycline, and levofloxacin against Mycoplasma and Ureaplasma species. The activity of AZD0914 was comparable to that of levofloxacin and doxycycline against Mycoplasma genitalium and Mycoplasma pneumoniae. The AZD0914 MIC90 against Mycoplasma hominis was 8-fold greater than that for levofloxacin. The AZD0914 MIC90 against Ureaplasma species was 4-fold less than that for azithromycin and 8-fold less than that for levofloxacin and doxycycline.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Azithromycin / pharmacology
  • Barbiturates / pharmacology*
  • Doxycycline / pharmacology
  • Humans
  • Isoxazoles
  • Levofloxacin / pharmacology
  • Microbial Sensitivity Tests
  • Morpholines
  • Mycoplasma / drug effects*
  • Mycoplasma genitalium / drug effects
  • Mycoplasma pneumoniae / drug effects
  • Oxazolidinones
  • Spiro Compounds / pharmacology*
  • Ureaplasma / drug effects*

Substances

  • Anti-Bacterial Agents
  • Barbiturates
  • Isoxazoles
  • Morpholines
  • Oxazolidinones
  • Spiro Compounds
  • Levofloxacin
  • Azithromycin
  • zoliflodacin
  • Doxycycline